Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 26.1% from a year ago
Total assets stood at $419.71M at the end of Q1 FY2026, up 26.1% from a year earlier and up 5.7% from the prior quarter. Over 3 fiscal years it compounded at +38.4% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +26.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 397.13M USD
- Year-over-year change
- +65.1%
- 3-year CAGR
- +38.4%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 397.13M | +65.1% |
| FY2024 | 2024-12-31 | 240.54M | +236.4% |
| FY2023 | 2023-12-31 | 71.5M | -52.3% |
| FY2022 | 2022-12-31 | 149.96M | — |
Total Assets vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of +26.1% is the 4th highest of 8, against a peer median of +23.4%.
- Over three fiscal years its annual growth of +38.4% compares with a peer median of +29.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Jun 2026 | $3.25B USD | +23.4% | +19.3% | |
| Sep 2026 | $848.23M USD | +57.5% | -3.5% | |
SEPNSepterna, Inc. | Sep 2026 | $619.4M USD | +2.1% | +154.6% |
| Mar 2026 | $504.51M USD | +23.0% | +38.2% | |
| Mar 2026 | $419.71M USD | +26.1% | +38.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $397.65M USD | +15.7% | +118.1% |
| Dec 2025 | €248.88M EUR | +109.2% | +29.0% | |
| Mar 2026 | $53.08M USD | +36.7% | +21.3% | |
| Peer median (excluding MAZE) | — | +23.4% | +29.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.